from people consecutively initiating ART in four purposively selected public outpatient clinics in three Vietnamese cities. At each study site, recruitment lasted for 6-10 months until the target sample size (range 120-130 individuals) had been reached. The viral load was measured in 501 samples; 490 samples (viral load ≥1000 copies/mL) were genotyped using a nucleotide population-based sequencing assay. Self-reported demographic and clinical data were elicited through interviews. We classified drug-resistance-associated mutations (DRMs) according to the 2009 WHO surveillance list.
Introduction
Individual and population benefits of ART have been well described. 1 -3 In 2013, the WHO recommended an ART initiation threshold of CD4+ T cell count ,500 cells/mm 3 for people living with HIV (PLHIV). 4 However, implementing the new guideline in the absence of viral load (VL) monitoring and with a shortage of salvage therapies can result in an increase in the prevalence of drug-resistant HIV strains. 5 People infected with drug-resistant HIV strains may develop early virological failure, 6 -8 subsequently leading to an accumulation and transmission of resistant strains, and they may also have a higher mortality rate. 9 Many resource-limited settings have adopted WHO guidelines to monitor the emergence of epidemics of HIV drug resistance . 10, 11 Key elements of the guidelines include the surveillance and monitoring of transmitted drug resistance, pretreatment drug resistance (PDR) and acquired drug resistance, which are essential indicators of outbreaks of HIV drug resistance. While a survey of ≤47 specimens from recently HIV-infected populations may be sufficient to categorize the prevalence of transmitted drug resistance as low (,5%), moderate (5%-15%) or high (.15%), 12 determining other indicators of HIV drug resistance, such as the levels of PDR among starters of ART, may require a much larger sample size. 13 Sax et al. 14 have argued that in settings with high levels of background drug resistance (.8.3%), baseline resistance testing is cost-effective and should be conducted as a part of routine care for PLHIV. Information on PDR is therefore crucial in ensuring the population-level effectiveness of first-line ART regimens in resource-limited settings. 13 Such data have not been investigated in large, representative surveys in Vietnam.
This study aimed to determine the prevalence and correlates of drug-resistance-associated mutations (DRMs) that confer resistance to at least one of the standard first-line antiretroviral drugs among ART entrants in Vietnam.
Patients and methods

Participants and data collection
Data were drawn from a baseline assessment of a cohort study at four purposively selected HIV outpatient clinics in Hai Duong, Hai Phong and Ho Chi Minh City during November 2009 to October 2010 for monitoring acquired drug resistance among people initiating first-line ART. The protocol of the study was developed based on a generic WHO HIV drug resistance protocol. 15 Each clinic from this study targeted a sample size of 120-130 participants through consecutive enrolment over a period of 6 -10 months.
PLHIV aged ≥18 years who met Vietnam's HIV treatment criteria at the time (WHO clinical stage I/II and CD4+ T cell count ,250 cells/mm 3 , or stage III and CD4+ count ,350 cells/mm 3 or stage IV regardless of CD4+ T cell count) 16 were included. Their criteria for ART initiation were assessed by local physicians in a routine ART initiation procedure at the study sites. Of note, patients who have previously received ART from a private physician may have frequent treatment interruptions due to high out-of-pocket payments for antiretroviral drugs, and discontinuation of therapy is well established as an important risk factor for acquired HIV drug resistance. 17 As a result, upon receiving these patients from the private sector, public physicians in Vietnam often recommend immediate ART without regard to the criteria for treatment initiation. We included these transferred patients in measuring the PDR level among ART starters at public clinics in this study. Moreover, women who had been previously exposed to antiretroviral drugs through programmes for the prevention of mother-to-child HIV transmission were also eligible for this study. In contrast, individuals who had discontinued ART but were restarted on ART at public clinics were excluded as they would have been exposed to public clinic-level factors (e.g. levels of adherence to ART and CD4+ T cell counts are frequently monitored among people receiving ART at public clinics), leading to biases in examining the risk of acquired drug resistance. Self-reported demographic and clinical data were collected through face-to-face interviews.
After the interview, a 6 mL blood specimen was collected for the measurement of plasma VL. For specimens with a VL ≥1000 copies/mL, nucleotide population-based sequencing was conducted for the entire protease gene and the first 200 codons of the reverse transcriptase gene. We used the 2009 WHO DRM surveillance list 18 
Statistical analysis
Participants were classified as having PDR to first-line drugs if they harboured HIV with DRMs that conferred resistance (level 3 or higher) to at least one of the standard first-line drugs. In Vietnam, first-line ART regimens during the study period included two NRTIs (stavudine or zidovudine plus lamivudine) and one NNRTI (efavirenz or nevirapine). 16 We used the x 2 or Fisher's exact test to compare the prevalence of drug resistance across stratified groups. All potential explanatory variables for PDR were included in a multivariate logistic regression model and backward elimination was used to determine the associated factors.
Ethical consideration
All participants provided written informed consent. The study protocol was reviewed and approved by both the local and international Institutional Review Boards of the Hanoi School of Public Health (reference number: 09-061/DD-YTCC) and the U.S. Centers for Disease Control and Prevention (reference number: 5734).
Results
Sample characteristics
Of 504 PLHIV who met inclusion criteria, specimens were collected from 501 participants (99.4%). Sequencing was not performed for 10/501 (2.0%) specimens with a VL ,1000 copies/mL. Of the 491 samples with a VL ≥1000 copies/mL, 490 (99.8%) were successfully amplified and sequenced for both protease and reverse transcriptase genes and were included in the analysis. Among participants whose samples were sequenced, 63.3% (310/490) were male; most reported injection drug use (40.4%, 198/490) or risks for sexual HIV acquisition without injection drug use (58.4%, 286/490). See Table 1 . Twenty-seven (5.5%) of the 490 participants had a history of receiving antiretroviral drugs through antenatal (3.9%, 19/490), private (1.2%, 6/490) and unknown (0.4%, 2/490) facilities. At ART initiation, the median CD4+ T cell count and VL were 106 (IQR 34-207) cells/mm 3 (data not shown) and 490 000 (IQR 161 000 -1 220 000) copies/mL, respectively. Compared with the study participants, the 14 subjects who were excluded were more likely to have prior exposure to antiretroviral drugs [35.7% (5/14) versus 5.5% (27/490), P ¼ 0.001] and a lower plasma VL (median 709 versus 490 000 copies/mL, P,0.001) ( Table 1 ).
Patients' genotypic resistance profiles
DRMs were identified in 17 participants (3.5%, 95% CI 2.2%-5.5%). Mutations associated with resistance to NRTIs, NNRTIs and PIs were identified in eight (1.6%), eight (1.6%) and four (0.8%) participants, respectively. Dual-class DRMs against NRTIs and NNRTIs were found in three women (0.6%). No triple-class DRMs were identified. Resistance to first-line NRTI or NNRTI drugs was identified in 13 of the 490 participants (2.7%; 95% CI 1.6% -4.4%), of whom 10 (77%) had high-level resistance, 2 (15%) had intermediate-level resistance and 1 (8%) had low-level resistance to at least one first-line antiretroviral drug ( Table 2 ).
Factors associated with PDR
In bivariate analyses, the prevalence of PDR to first-line drugs was marginally higher among participants who were not permanently living in the study cities due to fear that their HIV status would be exposed when accessing HIV treatment in clinics where they permanently resided [7.0% (3/43) versus 2.2% (10/447), P ¼ 0.097], Pham et al. Table 1 ). This finding did not change even after excluding the 27 antiretroviral-exposed participants (OR 3.74, 95% CI 1.06-13.10).
Discussion
The low prevalence of PDR to the first-line antiretroviral drugs reported in our study may indicate a low risk of early virological failure among ART patients in Vietnam. This is comparable to the recent levels reported among antiretroviral-naive PLHIV accessing HIV treatment in Ho Chi Minh City. 19 The short period since the roll-out of Vietnam's ART programmes (about 5 years until the present study), the successful use of standard combination triple-drug regimens and the simplified treatment management strategies in Vietnam 20 may have contributed to the low rate of PDR. 7 Our findings add to a growing body of evidence that PDR to first-line antiretroviral drugs is low among PLHIV initiating ART in resource-limited country settings, estimated to be 2.3% in other South-East Asian countries 8 and 4.8% in sub-Saharan African countries. 7 Nonetheless, we observed several major DRMs that confer high resistance to the available firstline drugs (NNRTI DRMs: K103N, Y181C, Y188C and G190A; NRTI DRMs: V75M and M184V). People harbouring HIV with such mutations may have early virological failure and may transmit drug-resistant HIV strains to the wider community. 6, 8 Given the rapidly rising prevalence of transmitted drug resistance from low (,5%) to moderate (5% -15%) levels in urban parts of Vietnam, 21 -23 it is anticipated that the prevalence of PDR may also rise accordingly. This emphasizes the need for routine surveillance programmes for both transmitted drug resistance and PDR in Vietnam to regularly update the knowledge base of the HIV drug-resistance disease burden in PLHIV, as well as for the timely and strategic selection of generic first-line ART regimens that are able to effectively suppress the virus and limit the spread of HIV drug-resistant strains. We found that injection drug use was significantly associated with PDR to first-line NRTI or NNRTI drugs. A Hanoi-based longitudinal study of 100 people who injected drugs on first-line ART found that active injection drug use was a risk factor for suboptimal adherence to treatment, 24 which is strongly associated with the emergence of HIV strains resistant to first-line NRTI/NNRTI drugs. 17 Frequent needle-sharing among HIV-infected people who inject drugs, as has been documented in Vietnam, 25 can lead to a higher risk of the transmission of both HIV WT and drug-resistant strains. That the association between injection drug use and PDR was retained in the multivariate regression Table 1 .
Continued
Characteristic
Patients who refused blood collection or whose blood specimens were unsuccessfully amplified (n¼14)
Patients whose blood specimens were successfully amplified and tested for HIV Age was associated with the prevalence of resistance to first-line drugs as a relatively straight line (data not shown) and was thus modelled as a linear association. c Logistic regression was not applied to these variables. d The categories are mutually exclusive. All participants who reported injection drug use were categorized as such, regardless of whether they reported other risks. The prevalence of resistance among the participants who injected drugs was compared with that among those reporting sexual HIV acquisition. e Three people refused blood collection. The median (IQR) of plasma VL in four excluded participants with a detectable VL was significantly lower than the median VL among the 490 study participants [709 (424 -1738) versus 490000 (161 000-1 220000) copies/mL, P,0.001]. Seven (two antiretroviral-naive and five antiretroviral-exposed participants) out of 11 excluded participants whose samples were available for testing had an undetectable VL (,250 copies/mL).
Pham et al. model in which the 27 antiretroviral-exposed participants were removed further supports the biological plausibility that the participants with PDR who injected drugs were more likely to have been infected with drug-resistant strains rather than having acquired them through prior unreported antiretroviral exposure. This study has limitations. First, our participants were recruited from four clinics in three cities so the findings may not be generalizable nationally. In response to WHO recommendations, Vietnam phased out stavudine in first-line ART regimens as of late 2011. 20 Thus, resistance to stavudine, which was observed in some participants, is unlikely to be a current clinical and public health concern. Importantly, the baseline characteristics of the 14 subjects excluded from this analysis were different from those of the rest of study participants, which may have led to biases in estimating the prevalence of PDR. Second, the temporal relationship between injection drug use and PDR to first-line drugs could not be determined from this cross-sectional study. Third, we may have misclassified some injection drug users as non-injection drug users if they concealed their injection drug use during interviews because of strict antidrug laws in Vietnam; however, such misclassification would have biased any association towards the null. Additionally, we did not collect data that might contribute to identifying the association between PDR and injection drug use (e.g. duration of injection, frequency of sharing injection equipment, drug-sharing networks and time from first diagnosis of HIV to presentation for HIV care and treatment). Fourth, selfreporting during face-to-face interviews may have limited the reliability of the information on prior antiretroviral exposure. For example, we documented many NRTI DRMs and NNRTI DRMs in two participants who self-reported as being antiretroviral-naive. Finally, the small number of cases with resistance to first-line antiretroviral drugs limited the analysis of some variables.
Our findings suggest that first-line ART may be effective in Vietnam and routine pretreatment genotyping and drugresistance testing may not be necessary due to low PDR levels. However, the continuing surveillance and prevention of antiretroviral resistance as per WHO recommendations 11 is essential for maintaining low levels of antiretroviral resistance and ensuring the effectiveness of first-line ART regimens in Vietnam. Our finding of significantly higher odds of PDR among people who injected drugs warrants further studies to more definitively identify the cause of this relationship.
